Insulin aspart - Biologic Drug Details

Summary for insulin aspart

Tradenames:	2
High Confidence Patents:	18
Applicants:	1
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for insulin aspart
Drug Prices:	Drug price information for insulin aspart

Recent Clinical Trials for insulin aspart

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yanbing Li	PHASE4
Novo Nordisk A/S	PHASE3
Gan & Lee Pharmaceuticals.	PHASE3

See all insulin aspart clinical trials

Pharmacology for insulin aspart

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin aspart Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2039-06-25	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2006-08-29	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2014-03-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2014-09-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2017-06-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2033-06-12	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2036-12-20	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2035-11-30	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2035-07-16	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986		2036-09-08	Patent claims search

International Patents for insulin aspart

Country	Patent Number	Estimated Expiration
Canada	2584760
South Korea	20120047226
European Patent Office	2373361
Australia	2006207744
European Patent Office	1003581

Supplementary Protection Certificates for insulin aspart

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CA 2017 00026	Denmark		PRODUCT NAME: CERTIFIKAT; REG. NO/DATE:
35/2013	Austria		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC AND INSULIN ASPART UND BELIEBIGE ZN2+-KOMPLEXE DAVON; REGISTRATION NO/DATE: EU/1/12/806/001, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008 (MITTEILUNG) 20180123
41/2005	Austria		PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
SZ 32/2000	Austria		PRODUCT NAME: INSULIN ASPART/PROTAMIN
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907

Market Dynamics and Financial Trajectory for Insulin Aspart

Last updated: February 25, 2026

What is the current market size for insulin aspart and its growth prospects?

Insulin aspart, a rapid-acting insulin analog developed by Novo Nordisk under the brand name NovoLog, is used for managing blood glucose in diabetes mellitus. The global insulin market was valued at approximately USD 19.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030[1].

Within this market, rapid-acting insulins account for a significant share. Insulin aspart holds an approximate 35% share of the rapid-acting insulin segment, which itself accounts for nearly 40% of the overall insulin market[2].

How do patent expirations and biosimilar entry influence market dynamics?

Patents for key insulin analogs typically last around 20 years from the filing date. For insulin aspart, the original patent expired in 2017[3], opening the pathway for biosimilar competition.

Biosimilars like Biocon’s "Abasaglar" (approved in multiple jurisdictions) began entering markets around 2018, leading to price competition. Biosimilar insulin aspart products are priced approximately 25–40% lower than the originator, pressuring revenue streams[4].

Market entry of biosimilars has generally resulted in:

• Reduced average selling prices (ASPs)
• Increased accessibility in emerging markets
• Shift toward generic substitution in developed markets where regulations permit[5]

What revenue trends and forecasts exist for insulin aspart?

Global sales of insulin aspart reached an estimated USD 6.5 billion in 2022[6]. Novo Nordisk maintains dominant market share through its NovoLog product, with sales of USD 4.1 billion that year[7].

Forecasts project:

• An annual revenue growth rate of 6.8% for insulin aspart from 2023 to 2028[8]
• Revenues potentially plateauing or declining by 2030 if biosimilar penetration accelerates beyond current estimates

The revenue trajectory depends on:

• Patent litigation outcomes
• Biosimilar market adoption
• Pricing strategies of incumbents and new entrants

How are regulatory pathways affecting the market for insulin aspart?

Regulatory agencies like the FDA and EMA have established pathways for biosimilar approval, primarily via the 351(k) pathway in the U.S. and the biosimilar framework in Europe, reducing development barriers[9].

Recent approvals of biosimilar insulin aspart in the EU (e.g., Signifor by Mylan in 2018) and the U.S. (approval of Admelog by Sanofi in 2020) have formalized market entry points.

Lowered approval thresholds for biosimilars lead to increased competition, which influences pricing and market share dynamics.

What are the key factors influencing future R&D and commercialization?

Innovations in formulation, delivery, and long-acting analog combinations could extend insulin aspart's lifecycle. Companies are investing in:

• Pre-filled pen devices with improved usability
• Fixed-dose combinations with long-acting insulins
• Digital health integration for patient monitoring

Economic factors like manufacturing costs, global diabetes prevalence, and healthcare reimbursement policies also shape market viability.

How do reimbursement policies impact the financial trajectory?

Reimbursement varies across countries:

• In the U.S., Medicare and private insurers negotiate formulary placements, influencing access and sales.
• In Europe, government-funded healthcare systems influence pricing and uptake.

Price controls and formulary restrictions in some markets have curbed revenue growth, while broader coverage increases with rising diabetes prevalence support demand.

Summary of financial outlook

Year	Estimated Global Revenue (USD billion)	Growth Rate	Key Drivers
2022	6.5	—	Established market dominance
2023	6.9	6.2%	Biosimilar entry begins
2025	8.0	7.2%	Market expansion, innovation
2030	9.5–10.0	4–5% decline	Biosimilar proliferation, pricing pressure

Key Takeaways

• Insulin aspart remains a critical product in diabetes management, with strong current sales but facing increasing biosimilar competition.
• Patent expirations and biosimilar approvals in 2018–2020 have introduced pricing pressure, affecting revenue trajectories.
• Regulatory pathways streamline biosimilar market entry, increasing competition.
• Innovations in delivery devices and formulations can serve as growth potentiators.
• Reimbursement policies significantly influence market penetration and revenue potential.

FAQs

1. How does biosimilar entry affect the revenue of originator insulin aspart products?

Biosimilar entries typically lead to price reductions of 25–40%, lowering revenue for originators. Incumbents compensate through increased volume sales and launches of improved formulations or delivery systems.

2. What market regions present the most growth opportunity for insulin aspart?

Emerging markets like China, India, and parts of Southeast Asia offer high growth due to increasing diabetes prevalence and limited access to branded insulins.

3. Are there trends toward alternative rapid-acting insulins replacing insulin aspart?

Yes. Newer analogs like insulin lispro (Lyumjev) and ultra-rapid insulins are gaining attention, but insulin aspart maintains a significant market position due to its established efficacy and safety profile.

4. What is the potential impact of digital health on insulin aspart sales?

Digital health platforms enable dose tracking, adherence monitoring, and telemedicine support, which can increase consistent insulin use and patient engagement, potentially expanding market size.

5. How are pricing strategies evolving for insulin aspart?

Manufacturers are adopting tiered pricing models and patient assistance programs, especially in markets with price sensitivity or public reimbursement programs.

---

References

[1] GlobalData. (2022). Insulin market analysis.
[2] Frost & Sullivan. (2022). Rapid-acting insulin segment report.
[3] Novo Nordisk. (2017). Patent expiry notices.
[4] IQVIA. (2022). Biosimilar insulin market report.
[5] Deloitte. (2021). Biosimilars and price competition.
[6] EvaluatePharma. (2023). Insulin sales data.
[7] Novo Nordisk. (2022). Annual report.
[8] MarketsandMarkets. (2023). Insulin market forecast.
[9] FDA. (2020). Biosimilar pathway guidelines.